SY10-3 - The Nationwide Cancer Genome Screening Project in Japan SCRUM-Japan GI-SCREEN

Abstract

SCRUM-Japan GI-SCREEN is the nationwide cancer genome screening project utilizing tissue-based next generation sequencing for patients with advanced gastrointestinal (GI) cancers, undertaken by National Cancer Center Hospital East collaborated with leading medical facilities and pharmaceutical companies. It was established to identify cancer patients with orphan-fractionated subtypes who likely to have promising therapeutic drugs since 2014 and to prepare easy-to-access platform where the patients can receive new treatment. At the time, it aimed to identify patients with advanced colorectal cancer (CRC) only, and since 2015, it evolved into the industry-academia collaborative project, called the SCRUM-Japan, which expanded to not only CRC but also non-CRC advanced GI cancers such as gastric, esophageal, liver, biliary tract, pancreatic, small intestine, GIST and so on. As of February 2018, more than 5,600 patients with advanced GI cancers have been registered. Notably, on-time clinico-genome data sharing with industries and academic institutions was also established. Recently, a prospective cohort registry projection has been initiated, which can potentially facilitate new drug R&D and its approval. More recently, an innovative projection, called the GOZILA, utilizing a leading liquid biopsy technology and several umbrella & basket type clinical trials has been initiated on 2,000 patients with advanced GI cancers to verify the clinical utility of analyzing cancer genome alteration by liquid biopsies. Additionally, a longitudinal study utilizing immune-genome panel for patients receiving immunotherapy to investigate dynamic transition among certain gene expression during clinical courses have been initiated. These efforts may contribute more to cancer precision medicine worldwide. Here we will present the present activities and future perspective in SCRUM-Japan GI-SCREEN.